Saturday, 30 July 2016

Unmet Needs of Patient Population in Emerging Economies to Provide Opportunities for Players in IT-enabled Healthcare, Says TMR

The IT-enabled healthcare market is highly fragmented with a large number of established players. Key players such as McKesson Corporation, Cerner Corporation, GE Healthcare, IMS Health Holdings, Inc., and Philips Healthcare have established themselves and collectively accounted for 14.3% of the market in 2013. Players are focusing on extensive product development and integrating across the value chain to reduce the overall cost of IT-enabled healthcare, states a new report by Transparency Market Research (TMR). 

The threat of new entrants is high as new players are attracted by the rapidly expanding market. The low initial investments required and the low regulatory barriers in the market also work in the favor of new entrants. However, new entrants require access to distribution channels and also partnerships would be vital for their growth. Since no external substitute for this technology is available, the threat of substitutes is expected to be low in the coming years.

Government Initiatives Promote Adoption of IT-enabled Healthcare Services

The various government initiatives across the globe are promoting the growth of IT-enabled healthcare market. Governments across the globe have been taking many efforts to ensure that people get technologically advanced healthcare infrastructure. The market is also driven by the rising incidences of chronic diseases. Since chronic diseases require long-term medication and continuous monitoring, IT-enabled healthcare solutions proves beneficial.

The rising administrative and operational cost of healthcare organizations have created a need for cost effective solution to provide healthcare to patients. As such, IT-enabled healthcare is attractive in terms of its cost-effectiveness and efficiency as compared to the conventional paper-based systems. Thus, the adoption of IT-enabled healthcare systems is expected to rise in the coming years.

Data Security: Matter of Concern for Healthcare Organizations

The information shared between different healthcare organizations is sensitive in nature and thus, requires a secure and reliable exchange method. Issues such as intrusion, data corruption, fraud, and damage, need to be addressed to increase the acceptance and adoption of IT-enabled healthcare services. Healthcare organizations need to implement strong information security management practices to ensure data privacy.

Interoperability issues associated with health IT solutions such as patient identifiers, electronic health records (EHRs), clinical guidelines, and other healthcare business processes are hampering the adoption of these services. Automation and streamlining of various IT healthcare solutions need to be done to make the services feasible. The different network protocols used are also causing interoperability issues between different IT systems. All these factors can deter the adoption of the IT-enabled healthcare services.

Emerging Economies to Hold Growth Opportunities

The emerging economies in Asia Pacific and Latin America offer huge growth opportunities for the IT-enabled healthcare market. The high number of underserved patients in India, Brazil, and China will create a heighted need for IT-enabled healthcare services. The growing geriatric population in Chile, Mexico, and Brazil is also likely to create a demand for IT-enabled healthcare services. Thus, major players such as Johnson and Johnson and Phillips Healthcare are expanding their manufacturing facilities in the emerging countries and taking advantage of the unmet needs of the underserved patient population.

According to the report, the global market opportunity in IT-enabled healthcare will rise from US$120.20 bn in 2015 to US$210.32 bn by 2020. By type, the healthcare system applications segment led not only in the past but is also expected to lead in the coming years in the global IT-enabled healthcare software market. The tele-health segment is expected to lead and account for 64.2% of the global IT-enabled healthcare services market by 2020. By end user, the public/private healthcare institutions segment is expected to lead by 2020 in the IT-enabled healthcare market. North America is expected to lead and account for 38% of the global market by 2020.

Thursday, 28 July 2016

Environmental Testing and Clinical Testing Market to Benefit from the Increasing Number of Government Initiatives

A new Transparency Market Research report states that the global E. coli testing market stood at US$1.2 bn in 2013 .and is predicted to reach US$2.1 bn by 2022. It is expected to expand at a CAGR of 6.58% from 2014 to 2022. The title of the report is, “E.coli Testing (Environmental Testing and Clinical Testing) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022.” 

View exclusive Global strategic Business report :
Escherichia coli (E. coli) are a diverse and large group of bacteria found in the environment, several foods, and intestines of animals and peoplehumans. Although the majority of strains of E. coli aren’t harmful, others can cause intestinal infections. The key symptoms of an E. coli infection include abdominal pain, diarrhea, and kidney failure. People having weakened immune systems, older adults, young children, and pregnant women are at a high risk of developing such complications. The kinds of E. coli that cause diarrhea are transmitted via contaminated food or water or via contact with affected persons or animals.

As per the report, the increasing initiatives taken by governments in favor of E. coli tests and the rising spread and high morbidity of E. coli are amongst the prime factors driving the growth of the market for E. coli testing. In addition, the development of drug-resistant species is also having a positive impact on the growth of the market. Polymerase chain reaction (PCR) tests being used for environment water testing has emerged as a key growth opportunity in the market. On the other hand, the soaring prices of enzyme-substrate tests in comparison with separate apparatus tests are inhibiting the growth of the market.

In terms of testing method, the report segments the market into clinical testing and environmental testing. The segment of environmental testing is further segmented into membrane filtration (MF), enzyme-substrate methods, and multiple tube fermentation (MTF). On the other hand, the segment of clinical testing is further segmented into enzyme immunoassays (EIA), polymerase chain reaction (PCR) tests, and others. Amongst these, on the basis of revenue, the segment of enzyme substrate tests hold the largest share of 80% in the market. On the basis of volume, this segment constitutes a share of 40% in the market. In terms of revenue, the segment of membrane filtration holds the largest share in the market.

On the basis of end use, the report segments the market into clinical and environmental. The segment of clinical E. coli testing is further segmented into diagnostic laboratories, hospitals, and physician offices. The segment of environmental E-coli testing is further segmented into bottle water suppliers, home and drinking water suppliers, waste water treatment organizations, and others including private well owners, government agencies, farm water testing, and groundwater testing, among others. Amongst these, E. coli testing has been highly demanded by bottle water suppliers and home and drinking water suppliers.

Geographically, the market is segmented into Europe, North America, Latin America, Africa, Rest of Africa, Asia Pacific, and Rest of the World (RoW). Amongst these, Europe led the market in 2013 due to the outbreak of foodborne infections within Germany in 2011 due to the E. coli O104:H4 strain. On the other hand, Asia Pacific is anticipated to be the most lucrative region in the market and is predicted to rise at a 6.92% CAGR from 2014 to 2022. This is owing to the increasing water pollution in rising economies such as India, Japan, and China.

Wednesday, 27 July 2016

Increasing Research into Longer Lasting Peptide Therapeutics Set to Bear Fruit

Peptides are short-chain amino acids used therapeutically in the treatment and management of several diseases, including major killers such as diabetes. Peptides are differentiated from proteins by the length of their amino acids; proteins have longer amino acid chains than peptides. Peptides such as insulin have been in therapeutic use for a long time and have helped drive investment in research into the therapeutic efficacy of peptides. Due to the growing investment in the sector, peptide therapeutics are becoming increasingly important in the global healthcare sector. 

Download Complete Healthcare Analytical Brochure:

According to Transparency Market Research, the global peptide therapeutics market is expected to exhibit a low yet steady 2.8% CAGR between 2014 and 2020. The market’s valuation is expected to rise from US$18.9 bn in 2013 to a projected US$23.7 bn by the end of the forecast period. Apart from the established therapeutic uses of peptides, their potential use in the treatment of various cancers, neurological disorders, hematological disorders, and cardiovascular and respiratory disorders is expected to be crucial for the market’s growth in the forecast period. 

How important will the growing prevalence of diabetes be for the peptide therapeutics market?

Despite the increasing research into the use of peptides in the treatment of various other diseases, the use of insulin in diabetes management remains the key application of peptide therapeutics. Diabetes has not shown any signs of slowing down since insulin became the first therapeutically used peptide; in fact, its prevalence has grown rapidly in the last few decades, as the increasing prosperity in developed economies has made various risk factors for diabetes increasingly accessible to the average consumer. The disease is expected to remain a global healthcare concern in the coming years, driving the market for advanced insulin products.

Apart from the use of insulin in diabetes management, what is the key driver for the peptide therapeutics market?

The increasing innovation of advanced peptide therapeutics is another key driver for the global peptide therapeutics. As the infrastructure for clinical research into peptide therapeutics becomes more refined, the use of high-precision methods and tools has allowed market giants to come up with safe and effective peptide therapeutics. Due to the increasing consumer satisfaction brought about by technological progress, collaboration between biotech and pharmaceutical companies is expected to be a prominent feature of the global peptide therapeutics market in the coming years.

A key advancement in the field of peptide therapeutics is the innovation of stable peptide molecules that aren’t degenerated by the body as quickly as conventional peptides. The conventional mode of delivering peptide therapeutics has involved permeability enhancement, which comprises various techniques to ease the entry of the peptide into the vascular network around the digestive tract. However, most slow-acting peptide therapeutics fail to achieve significant bioavailability through this procedure. The promising recent development of a phase-II GLP-1 analog that has a circulating half life of around one week by Novo Nordisk could open the doors for peptide therapeutics to be used on a wider scale in the treatment of several other diseases.

Which region presents the most lucrative opportunities for producers of peptide therapeutics?

Even though North America and Europe currently account for a majority share in the global peptide therapeutics market, the future of the market is expected to be dominated by Asia Pacific. The medical research sector in Asia Pacific has undergone significant development in the last few years, and the high prevalence of diabetes in Asian races means peptide therapeutics are not an entirely novel field.

Monday, 25 July 2016

Clinical Information Systems (CIS) used in medical stores and rechecks all information

Clinical Information Systems (CIS) is a computer aided system that manages, stores and rechecks all medical information in hospitals such as health history of patients, prescriptions, doctor\'s notes and any other special comment whereas all information is electronically kept together. By capturing clinical data CIS makes the decision making process and clinical care delivery more efficient and effective and also helps to replace the paper work. Apart from this it helps by computerization of repetitive tasks, high accuracy, automated recording of medical equipments observations and results. Functions of clinical information systems are not limited to a single area such as diagnosis data management of laboratory data management but are more widespread and comprising practically all aspects of clinical information.

Request free Sample pages of premium Research Report:

According to study conducted by The Johns Hopkins Medicine Institute, 40 percent of physicians exceeded their expected number of patients seen in a typical day. Increasing prevalence and incidences of various critical diseases have increased the load on hospitals to diagnose and treat more number of patients with high level of efficiency and accuracy. All these factors have lead to increase in demand for the sophisticated management systems to handle patients’ clinical related data. Looking at the technologically advancement in this market and increasing patient load on every hospital in both developed and developing countries, it can be estimated that there may be considerable growth of the market in coming years. At the same time growing number of state of art healthcare facility centers across the world, may drastically increase demand for the CIS. On the other side, rapidly changing technology, high cost involved in installation and maintenance of CIS and requirement of professional training to handle CIS hindering the growth of the market. Clinical information systems are widely spread in western world healthcare providers, however, their function are mainly restricted to financial and administrative functions, rather than having a direct support for patients or assisting physicians and other professionals in their daily work.

Market for clinical information systems can be segmented geographically and according to its usage in various types of services and products offered such as cloud based and web based. Geographically CIS market is segmented in four regions namely North America, Europe, Asia-Pacific and Rest of the World. North America and Europe are the leading geographic regions followed by Asia-Pacific and Rest of the World respectively. On the other side, according to services, CIS market can be segmented in cloud based and web based market, out of which though web based is major but growth for the cloud based systems are comparatively on higher side. Parallel to this, the market for CIS can be divided in three categories namely hardware, software and services. The market for hardware and software is relatively higher than that of services required for maintaining CIS. There are some companies which are catering exclusively in all these three segments in the market. There are special guidelines issued by U.S. FDA regarding the use of information systems in healthcare facilities majorly focused on easy to use, data safety and training of the personnel.

Some of the market players in Clinical Information Systems market include Clinicmaster, Quintiles, Accenture, Allegro CTMS, iMDsoft and thermo scientific, Surgical Information Systems LLC.  

Saturday, 23 July 2016

Exocrine Pancreatic Insufficiency Market to Difficult Drug Approval Procedures Could Hamper Growth

Transparency Market Research has published a new market report titled, “Exocrine Pancreatic Insufficiency Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 - 2023.” According to the report, the exocrine pancreatic insufficiency market is anticipated to expand at a CAGR of 8.3% from 2015 to 2023 to reach US$2.85 Bn by 2023.

Get Free Sample Research Report:
Exocrine pancreatic insufficiency (EPI) is a condition characterized by the deficiency of the exocrine pancreatic enzymes, causing failure to digest food properly. Exocrine pancreatic insufficiency is caused due to damage to pancreas. The common causes of EPI are cystic fibrosis, chronic pancreatitis, and Shwachman-Diamond syndrome. The peculiar symptoms of EPI include frequent diarrhea, weight loss, foul-smelling greasy stools, gas and bloating, and stomach ache. Exocrine pancreatic insufficiency is treatable with pancreatic enzyme replacement therapy, which helps in digestion, improves malabsorption and vitamin deficiencies, and fuels weight gain.

Pancreatic enzyme replacement therapy products contain a defined amount of digestive enzymes such as lipases, proteases, and amylases, which are required by the body to metabolize fats, proteins, and sugar from food. Without these enzymes, patients with EPI are less capable of absorbing vital nutrients from food and can become undernourished. Effective management of EPI includes life-long pancreatic enzyme replacement therapy (PERT), lifestyle modifications, modifications with specialized food supplements such as vitamins and nutrients that do not require pancreatic enzymes for digestion, and transplantation of pancreatic cells.

Factors such as the increasing prevalence of diseases such as cystic fibrosis, chronic pancreatitis and diabetes are contributing to an increase in the prevalence of exocrine pancreatic insufficiency. According to recent data released by the Cystic Fibrosis Foundation, about 30,000 people are living with cystic fibrosis in the U.S. and 70,000 across the globe. Approximately 1,000 new cases of cystic fibrosis are diagnosed each year in the U.S. With such alarming rise in the number of people suffering from cystic fibrosis, the risk of incidence related to the disease also increases. People suffering from cystic fibrosis face breathing complications as mucus clogs their lungs and makes them susceptible to infections. Thick mucus also chokes the pancreas and obstructs the release of digestive enzymes leading to the deficiency of these enzymes. EPI is observed in a considerable proportion among the CF patients, with roughly 50% of children with CF suffering from this condition at birth. In addition, 25% of the population develops EPI within the first six months of life. Furthermore, 15% develop EPI in late childhood. According to recent data released by Aptalis (Allergan), chronic pancreatitis is observed in roughly 0.03% to 0.04% adults in the U.S. Of these, around 30% to 40% are expected to develop EPI over a span of 10 years.

Prevalence of EPI is expected to rise due to increase in the number of people suffering from diabetes. According to data published by the Centers for Disease Control and Prevention in 2014, the prevalence of diabetes in the U.S. has increased from 4.40% in 2000 to 7.18% in 2013. Examinations of people suffering from diabetes have shown greater than normal inflammation and damage to pancreatic tissue, signifying the increase in the risk of exocrine pancreatic insufficiency in people suffering from diabetes. The EPI market is also driven by the opportunities offered by developing countries. With an increasing incidence of diseases in this region, demand for PERT products is expected to grow in the next few years. However, stringent FDA regulations for the approval of PERT products are expected to hamper the growth of this market.

Major players in this market are AbbVie, Inc. (U.S.), Allergan plc (Ireland), Nordmark Arzneimittel GmbH & Co. KG (Germany), Digestive Care, Inc. (U.S.), Cilian AG (Germany), Anthera Pharmaceuticals, Inc. (U.S.), Janssen Pharmaceuticals, Inc. (U.S.), and AzurRx BioPharma, Inc. (U.S.).

Wednesday, 20 July 2016

Global Sunitinib Malate Capsules Market Industry Benefits and Opportunities

Global Sunitinib Malate Capsules Market: Overview

Sunitinib malate is a small-molecule medicine that has been proven to be effective in blocking multiple receptor tyrosine kinases (RTKs). The potential antineoplastic activity of sunitinib has led to it being regarded as an effective agent in inhibiting cell proliferation and angiogenesis. Sunitinib capsules have been approved for use in treating pancreatic neuroendocrine tumors, kidney cancer, and gastrointestinal stromal tumor (GIST).

Sunitinib malate capsules received the U.S. FDA’s approval for use in the treatment of renal cell carcinoma and GIST on January 26, 2006. They also subsequently received approval from the European Medicine Agency in July 2006. Two years later, on April 16, 2008, the drug was approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).

The aforementioned regions have thus emerged as the leading markets for sunitinib malate capsules, which are marketed by Pfizer as Sutent. Pfizer has market exclusivity over sunitinib malate capsules until 2021, which has made them an important revenue source for Pfizer, which had been losing revenue owing to the patent expiration of Lipitor in November 2011. The total sales of sunitinib malate were estimated at more than US$1 bn as of 2015.

This report examines the sales potential of sunitinib malate capsules in key regional markets such as the U.K., Japan, and the U.S. It also analyzes changes in the regulatory environment that could potentially impact the trajectory of the global sunitinib malate capsules market. Protected by patents, Sutent is expected to enjoy a healthy rise in revenue for the better part of the report’s forecast period.

Global Sunitinib Malate Capsules Market: Drivers and Restraints

The increasing prevalence of pancreatic cancer is a major driver for the global sunitinib capsules market. According to the American Cancer Society, around 53,000 Americans are expected to be diagnosed with pancreatic cancer in 2016, with close to 42,000 of them expected to succumb to it. Due to the relative inaccessibility of the pancreas, detecting and removing pancreatic tumors is more difficult than other tumors. As a result, the use of sunitinib malate capsules to treat pancreatic tumors is increasing.

The increasing prevalence of pancreatic neuroendocrine tumors, in particular, is a key driver for the global sunitinib malate capsules market. Sunitinib malate was approved by the FDA in May 2011 for the treatment of pancreatic neuroendocrine tumors that have proven difficult to extract surgically or have already metastasized.

However, one of the key restraints acting against the global sunitinib malate capsules market’s growth is the high cost of Sutent. It ranks among the most expensive drugs currently being marketed, which puts it out of the reach of the average consumer in the absence of sufficient reimbursement. Moreover, studies have also shown that Sutent is associated with hepatotoxicity – a condition that can lead to liver failure and even death. Adverse cardiovascular events have also been reported during clinical trials, which could discourage adoption of the drug.

Global Sunitinib Malate Capsules Market: Regional Outlook 

It is estimated that the global market for sunitinib malate capsules will remain concentrated in the developed G7 countries, where the sales of the drug are currently the highest. Through the latter half of the report’s forecast period, after the expiration of the patents on Sutent, the market for sunitinib malate capsules is expected to develop rapidly in the mass volume markets of China and India. This could cause a significant shift in the overall dynamics of the global market for sunitinib malate capsules.

The report has been compiled to aid entities such as contract research organizations, pharmaceutical companies, regulatory authorities, and health insurance companies in making strategy decisions regarding the global sunitinib malate capsules market. The report offers a comprehensive evaluation of the market by providing in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions, due to which the research report serves as a repository of analysis and information for every facet of the market.

Full Research Report on Global Sunitinib Malate Capsules Market:

Thursday, 14 July 2016

Improving General Fertility Rate Steers Sales of Pregnancy Products Worldwide, says TMR

The top three players leading the U.S. pregnancy product market collectively hold a share of 25% in the overall market, Transparency Market Research (TMR) finds. The largest share of about 10% is held by Expanscience Laboratories, Inc. Its leading brands, Mustela and Piascledine 300, are spread over 97 countries, garnering a remarkable presence and indomitable revenues. Currently, Expanscience Laboratories, Inc. has 808 patents registered around the world, which will give it a competitive advantage over others in the foreseeable future.

E.T Browne Drug Co., Inc. is the next big contender in the overall market with a share of about 8.1%. The unique ingredients used to make effective line of products and the usage of cocoa butter to enhance the quality of products are giving this company the much-needed boost in the vendor landscape. TMR also observed that the third important player in the overall market, Clarins, has been winning a significant share as the company has toiled towards introducing a new treatments for body and face over the past few years. A majority of its luxury products by Clarins are centered around pure plant extracts, which has been a clear choice amongst pregnant women. 

Rising Fertility Offers Growth Opportunities to Pregnancy Products

“The rise in general fertility rate has been an important driver for the market,” says a TMR analyst. “As the number of pregnancies are expected to go up in the coming years in the U.S. it is also going to make women prone to various pregnancy-related changes, thereby making them potential customers for these products” added the analyst. To reduce the negative impact of changes to the skin during pregnancy such as sagging, stretch marks, and itching the majority of the women are very likely to invest in various pregnancy products.

Advertisements Play Crucial Role in Defining Success of Overall Market

The indelible impact of advertisements through newspapers, television, magazines, and other forms of media are also likely to create a fertile space for the U.S. pregnancy products market. Analysts anticipate that the stretch mark minimizer will be the popularly sold product in the overall market due to its long-term necessity during the course of pregnancy, affordable pricing, and non-invasive usage. The easy availability of stretch mark minimizers through various distribution channels is also likely to boost the sale of these products.

The safety of pregnancy products has always been a big restraint for this market. For instance, several topical solutions contain retinoids, which is known to cause birth defects if administered orally. However, how much of it is actually absorbed by the skin and what is its exact impact still remain under study.

Several players in this market are trying to develop products that have natural extracts as opposed to synthetic chemicals to mitigate the risk of health problems these products can lead to.

The U.S. pregnancy products market was valued at US$266.6 mn in 2014. However, analysts are projecting that the opportunity of this market will value US$439.2 mn by the end of 2023. To reach this valuation, the market is anticipated to sprint at a pace of 5.7% CAGR between 2015 and 2023. As of 2014, the stretch mark minimizer held a formidable share of 50% in the overall market and is expected to retain this dominance in the coming years as well. The other product segments are anticipated to surge at a CAGR of 6.3% during the forecast period.

Full Research Report on Global Pregnancy Products Market:

Thursday, 7 July 2016

Hospital Infection Therapeutics Market to Increasing Number of Pipeline Drug Molecules

A new market research study, titled “Hospital Infection Therapeutics Market  - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020,” has been published by Transparency Market Research, providing a comprehensive analysis of the market. The major driving factors, barriers, and current trends of the global hospital infection therapeutics market have been included in the scope of the research report. 

As per the research study, in 2013, the global market for hospital infection therapeutics was valued at US$3.1 bn and is estimated to reach US$3.6 bn by the end of 2020. The market is predicted to exhibit a 3.10% CAGR between 2014 and 2020.

Hospital-acquired infections are majorly caused by fungal, bacterial, and viral pathogens. Several cases of hospital infections are acquired from the intensive care units of hospitals. A huge number of antimicrobial drugs have demonstrated their capability in treating a wide range of hospital infections. The increasing number of pipeline drug molecules in the hospital infection therapeutics market is one of the biggest opportunities for the growth of the market. In addition, the absence of skilled staff in developing and underdeveloped countries and growing prevalence of several hospital infections are the major factors expected to fuel the growth of the market in the next few years.

Based on the major prominent types of drugs in the market, the global market for hospital infection therapeutics has been segmented into antiviral, antibacterial, and antifungal drugs. In 2013, the antibacterial drugs segment dominated the market, accounting for a 70.7% share in the global market for hospital infection therapeutics. This segment is projected to grow at a fast pace in the next few years. The research study has further analyzed the major drugs in the pipeline, including Plazomicin, Ceftolozane, Delafloxacin, Eravacycline, Surotomycin, Tedizolid, Amikacin Inhale, MK-3415A, CAZ AVI, Dalvance, and Oritavancin.

On the basis of type of infection, the global market for hospital infection therapeutics has been categorized into gastrointestinal disorders, hospital-acquired pneumonia, urinary tract infections, surgical site infections, bloodstream infections, and other infections. In 2013, the hospital-acquired pneumonia segment accounted for a 20% share in the global market for hospital infection therapeutics. Nevertheless, the urinary tract infections segment is anticipated to grow rapidly in the near future.

Currently, North America leads the overall market and is estimated to remain in the leading position in the next few years. North America is closely trailed by Europe. The rapid growth of these two regional markets can be attributed to the increasing healthcare awareness and growing demand for advanced drugs. On the other hand, the Asia Pacific market for hospital infection therapeutics is estimated to witness the fastest growth throughout the forecast period.

Furthermore, the research report talks about the competitive scenario of the global market for hospital infection therapeutics. Detailed profiles of the prominent players have been discussed in the scope of the research study. Some of the leading players operating in the market are Bayer AG, Johnson & Johnson Services, Inc., Actavis plc, Sanofi, Bristol-Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline plc, Pfizer, Inc., AstraZeneca plc, and Cubist Pharmaceuticals, Inc.

Full Research Report on Global Hospital Infection Therapeutics Market:

Wednesday, 6 July 2016

Multiple Sclerosis Drugs Market - Global Analysis and Industry Trends from 2018

Multiple sclerosis is a progressive, immune-mediated, neurodegenerative disorder that can also prove to be fatal. The rising incidence of multiple sclerosis around the globe and strong R&D efforts by leading players and government organizations have significantly boosted the global multiple sclerosis drugs market. 

Q. What is the current scenario of multiple sclerosis around the world?

A. According to research conducted by the Multiple Sclerosis Association of America, an estimated 2 to 2.5 million people are affected by multiple sclerosis around the globe. While the disease affects people between the age of 20 and 50, women are two or three times more likely to be affected by MS than men. A 2008 assessment of multiple sclerosis by the World Health Organization reveals that the prevalence of the condition is greatest in Europe, followed by the Eastern Mediterranean, and North America. People in high-income countries are more likely to be affected by the neurological disease; however, the WHO study emphasizes that multiple sclerosis is a global disease and not one solely of the more developed “western” countries. 

Q. How are major breakthroughs in the overall multiple sclerosis market affecting the demand for multiple sclerosis drugs?

A. The overall market for multiple sclerosis is no doubt witnessing some groundbreaking developments in recent years. In June 2016, scientists in Canada developed a radical therapy that has shown complete long-term remission from multiple sclerosis. This trial is the first in the world to halt the progression of this debilitating disease and even reverse its symptoms. The new therapy is known as immunoablation and autologous hematopoietic stem cell transplantation (IAHSCT) and involves the use of chemotherapy to completely eradicate the damaged immune system and reboot it by transfusing bone marrow cells. Some participants of the clinical trial were able to return to school, work, get married and have children, and regain the ability to drive. 

Although this trial has the potential to considerably change the course of the global multiple sclerosis market, developments such as these act as a deterrent to the multiple sclerosis drugs market. The demand for drugs have been taking a hit owing to an increasing number of MS patients opting for surgical treatments rather than drugs. 

Q. How is the progress of the multiple sclerosis drugs market dependent on the success or failure of major players?

A. Biogen Inc. is one of the leading companies in the global multiple sclerosis drugs market. Its performance and contribution over the years in the form of innovative and high-efficacy drugs and a strong pipeline has significantly driven the market. However, even major players such as Biogen can cause a sudden dip in the multiple sclerosis drugs market. Biogen’s experimental drug for multiple sclerosis – called opicinumab – was one of the most awaited drugs for the year and patients as well as healthcare providers were hopeful of the drug’s ability to change the course of multiple sclerosis. However, the drug failed in a mid-stage trial, missing the main as well as secondary goals for the treatment of the neurological disease. Most of Biogen’s revenue comes from MS drugs and this failure is a major setback for the company. This is also means a hitch in the progress of the global multiple sclerosis drugs market. 

Full Research Report on Global Multiple Sclerosis Drugs Market:

Tuesday, 5 July 2016

Transdermal Skin Patches Market to Surge owing to Inefficiency of Traditional Medication

Transdermal patches are pharmaceutical preparations that contain active substances. These patches apply the diffusion mechanism and are effectively used for hormonal and cardiac disorders. Transdermal skin patches are a new trend in the global skincare market. Skin gels and patches are among the modern methods used for treating many ailments. As per new research from Transparency Market Research, the global transdermal skin patches market is expected to exhibit rapid growth during the period from 2013 to 2019. 

The report, titled ‘Transdermal Skin Patches Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,’ states that the market will benefit from the rising use of transdermal skin patches as a supplement to traditional care methods. The rising number of skin diseases is also expected to propel the demand for transdermal skin patches. Transdermal skin patches deliver treatment in a non-invasive way and offer many benefits. Patches deliver medicines to the body gradually yet constantly. Skin patches are painless and bypass the acidic environment present inside the digestive system. 

The first skin treatment patch, approved by the U.S. Food and Drug Administration in 1979, was used for curing motion sickness. Since then, there have been many patches introduced in the global market to treat various diseases including Parkinson’s disease and Alzheimer’s. With advancements in the medical devices sector, leading players have introduced many transdermal skin patches to cure skin issues.  

Transdermal skin patches comprise an inner covering and an outer covering. The inner covering contains active drugs that are delivered to cure the affected area. Transdermal gels are commonly used for treating various skin diseases as they are effective and offer quick relief. Dermal patches replace traditional oral medications in many gastric conditions including vomiting and diarrhea. Dermal patches minimize the inconvenience caused by parenteral therapies. 

For a detailed analysis, the report’s authors have regionally divided the global transdermal skin patches market into Asia Pacific, Europe, North America, and Rest of the World. Presently, companies such as Mylan Pharmaceuticals Inc., Teva, Accrux Ltd., 3M Pharmaceuticals, and Access Pharmaceuticals are playing a dominant role in the global transdermal skin patches market. 

Considering the growing limitations of traditional care methods to treat specific skin problems, leading players are concentrating on introducing new dermal skin patches in the global market. Analysts predict that mergers and partnerships between new entrants and leading manufacturers will create new growth opportunities in the global transdermal skin patches market. 

Full Research Report on Global Transdermal Skin Patches Market: